Solanezumab Does Not Slow Cognitive Decline in Preclinical Alzheimer Disease
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
WEDNESDAY, July 19, 2023 -- For patients with preclinical Alzheimer disease, solanezumab does not slow cognitive decline, according to a study published online July 17 in the New England Journal of Medicine to coincide with the annual Alzheimer's Association International Conference, held from July 16 to 20 in Amsterdam.
Reisa A. Sperling, M.D., from Massachusetts General Hospital in Boston, and colleagues tested solanezumab, which targets monomeric amyloid, in a phase 3 trial involving persons aged 65 to 85 years with preclinical Alzheimer disease and elevated brain amyloid levels. Participants were randomly assigned to receive solanezumab or placebo (578 and 591, respectively).
The researchers found that the mean change in the Preclinical Alzheimer Cognitive Composite score was −1.43 and −1.13 in the solanezumab and placebo groups, respectively, at 240 weeks. Amyloid levels on brain positron emission tomography increased by a mean of 11.6 and 19.3 centiloids in the solanezumab and placebo groups, respectively. Less than 1 percent of the participants in each group had amyloid-related imaging abnormalities (ARIA) with edema. ARIA with microhemorrhage or hemosiderosis occurred in 29.2 and 32.8 percent of participants in the solanezumab and placebo groups, respectively.
"The anti-monomeric amyloid antibody solanezumab did not slow the progression of preclinical Alzheimer's disease as compared with placebo on the basis of the primary or secondary cognitive and functional end points over a period of 4.5 years," the authors write.
The study was partially funded by Eli Lilly, which also supplied the active medication and placebo, and in-kind support from Avid Radiopharmaceuticals and Cogstate.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted July 2023
Read this next
Preeclampsia Linked to Increased Risk for Young-Onset Dementia
FRIDAY, May 31, 2024 -- Individuals with preeclampsia have an increased risk for young-onset dementia, according to a research letter published online May 30 in JAMA Network...
Self-, Partner-Reported Cognitive Decline Linked to Tau
THURSDAY, May 30, 2024 -- Individuals who self-report and whose partners report cognitive decline have greater tau, which is driven by elevated beta-amyloid (Aβ), according...
Socioeconomic Status Transitions Tied to Dementia Risk
THURSDAY, May 23, 2024 -- Upward and downward socioeconomic status (SES) transitions are associated with the risk for dementia and the length of dementia-free periods during the...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.